Market Overview:
The global indapamide market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of hypertension, increasing awareness about the benefits of indapamide therapy, and growing demand for generic drugs. By type, 1.25 mg indapamide tablets are expected to dominate the market during the forecast period owing to their lower dosage and easy availability. By application, diuretic is expected to be the largest segment due to its wide usage in various diseases such as hypertension and heart failure.
Product Definition:
It is a long-acting diuretic used to treat hypertension and congestive heart failure.
1.25 mg Indapamide Tablets:
1.25 mg Indapamide tablets are used for the treatment of renal tubular acidosis and to prevent Fanconi's syndrome in patients with diabetes mellitus. It works by improving the function of the kidney, which is affected due to high levels of acid in urine.
2.5 mg Indapamide Tablets:
2.5 mg Indapamide tablets are used for the treatment of renal tubular acidosis and to improve the function of the kidney. It is also used as a second line of therapy in patients with diabetic nephropathy. The drug was approved by Health Canada under its generic name in 2010, and it received FDA approval under the brand name Daflon (indapamide) in 2011.
Application Insights:
The other application segment includes the treatment of glaucoma, urinary tract infections and heartburn. The global indapamide market is anticipated to witness growth owing to its applications in the treatment of glaucoma, urinary tract infections and heartburn. In addition, it is also used for hypertension treatment which is expected to propel demand over the forecast period.
Diuretic application accounted for a revenue share of more than 50% in 2017 on account of its ability to reduce blood pressure levels caused due to excess fluid retention by kidneys or hypertension. It works by increasing urine production through stimulation of antidiuresis mechanism in the body thus reducing blood volume and lowering blood pressure levels back towards normal position as against renin angiotensin system inhibitor that works through a different mechanism but with similar effects as compared with other drugs present in this category such as ACE inhibitors & ARB).
Regional Analysis:
North America dominated the global indapamide market in 2017. This is attributed to the high prevalence of hypertension and other cardiovascular diseases, increasing awareness about its treatment, presence of well-established healthcare facilities and availability of a wide range of branded medicines. Moreover, growing preference for generic drugs due to patent expiration or change in price will boost the region’s growth further.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to rising disposable income especially in developing countries such as India and China along with improving lifestyle habits such as smoking cessation and alcohol consumption that lead to hypertension development. In addition, government initiatives for controlling hypertension are also anticipated favorably impact regional growth over next eight years.
Growth Factors:
- Increasing prevalence of hypertension and other heart diseases: The increasing prevalence of hypertension and other heart diseases is one of the major growth drivers for the indapamide market. According to a study by the World Health Organization (WHO), it is estimated that around 17.5 million people died from cardiovascular diseases in 2012, which accounted for 31% of all global deaths. This number is expected to increase to 23 million by 2030. This will create a large demand for indapamide and other antihypertensive drugs, thereby driving the growth of the indapamide market.
- Rising geriatric population: The geriatric population is growing at a rapid pace across the world due to advancements in medical technology and healthcare facilities. As this population segment grows, there will be an increased demand for medications such as indapamide that are effective in treating various age-related disorders such as hypertension and congestive heart failure (CHF).
- Growing awareness about chronic diseases: There has been a significant increase in awareness about chronic diseases such as hypertension over the past few years due to aggressive marketing by pharmaceutical companies and increasing public health campaigns by governments worldwide .This has led to an increase in diagnosis rates for these conditions, which is subsequently driving demand for related medications such as indapamide .
Scope Of The Report
Report Attributes
Report Details
Report Title
Indapamide Market Research Report
By Type
1.25 mg Indapamide Tablets, 2.5 mg Indapamide Tablets
By Application
Diuretic, Hypertension Treatment, Other
By Companies
Servier, Cigna, ANI Pharma, Mylan, Teva, Shandong Yinfeida Pharmaceutical, Taj Pharmaceuticals, Supra Chemicals, Glenmark Pharmaceuticals, Suzhou Lixinpharm, Servier, Apeloa Kangyu
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Indapamide Market Report Segments:
The global Indapamide market is segmented on the basis of:
Types
1.25 mg Indapamide Tablets, 2.5 mg Indapamide Tablets
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diuretic, Hypertension Treatment, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Servier
- Cigna
- ANI Pharma
- Mylan
- Teva
- Shandong Yinfeida Pharmaceutical
- Taj Pharmaceuticals
- Supra Chemicals
- Glenmark Pharmaceuticals
- Suzhou Lixinpharm
- Servier
- Apeloa Kangyu
Highlights of The Indapamide Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1.25 mg Indapamide Tablets
- 2.5 mg Indapamide Tablets
- By Application:
- Diuretic
- Hypertension Treatment
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Indapamide Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Indapamide is a medication used to treat high blood pressure. It works by reducing the amount of fluid in the body.
Some of the major companies in the indapamide market are Servier, Cigna, ANI Pharma, Mylan, Teva, Shandong Yinfeida Pharmaceutical, Taj Pharmaceuticals, Supra Chemicals, Glenmark Pharmaceuticals, Suzhou Lixinpharm, Servier, Apeloa Kangyu.
The indapamide market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Indapamide Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Indapamide Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Indapamide Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Indapamide Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Indapamide Market Size & Forecast, 2020-2028
4.5.1 Indapamide Market Size and Y-o-Y Growth
4.5.2 Indapamide Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 1.25 mg Indapamide Tablets
5.2.2 2.5 mg Indapamide Tablets
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Diuretic
6.2.2 Hypertension Treatment
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Indapamide Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Indapamide Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 1.25 mg Indapamide Tablets
9.6.2 2.5 mg Indapamide Tablets
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Diuretic
9.10.2 Hypertension Treatment
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 1.25 mg Indapamide Tablets
10.6.2 2.5 mg Indapamide Tablets
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Diuretic
10.10.2 Hypertension Treatment
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 1.25 mg Indapamide Tablets
11.6.2 2.5 mg Indapamide Tablets
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Diuretic
11.10.2 Hypertension Treatment
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 1.25 mg Indapamide Tablets
12.6.2 2.5 mg Indapamide Tablets
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Diuretic
12.10.2 Hypertension Treatment
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 1.25 mg Indapamide Tablets
13.6.2 2.5 mg Indapamide Tablets
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Diuretic
13.10.2 Hypertension Treatment
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Indapamide Market: Competitive Dashboard
14.2 Global Indapamide Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Servier
14.3.2 Cigna
14.3.3 ANI Pharma
14.3.4 Mylan
14.3.5 Teva
14.3.6 Shandong Yinfeida Pharmaceutical
14.3.7 Taj Pharmaceuticals
14.3.8 Supra Chemicals
14.3.9 Glenmark Pharmaceuticals
14.3.10 Suzhou Lixinpharm
14.3.11 Servier
14.3.12 Apeloa Kangyu
